Merck vs Precigen
Merck (MRK) and Precigen (PGEN) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $330B
- Last close
- $133.72
- 12 months
- +40.8%
- Market value
- $1.51B
- Last close
- $4.21
- 12 months
- +8.0%
At a glance
- The biggest part of Merck's revenue is Pharmaceutical, 89% of the total in its last annual report.
- By market value, Merck ($329.7B) is about 218 times Precigen ($1.5B).
- Over the last 12 months Merck's share price moved +40.8% and Precigen's +8.0%; against the S&P 500 that is +35.1 points and +2.2 points.
- In their last fiscal years Merck kept 28.1% of revenue as net income and Precigen -2588.2%.
- In the last 90 days insiders reported 0 open-market purchases at Merck and 0 at Precigen; members of Congress disclosed 3 trades in Merck and 0 in Precigen.
- Next results: Merck Feb 2, 2027, Precigen not announced.
How each one makes money: Merck revenue
Share prices on one chart
Merck and Precigen, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Merck MRKNYSE · Pharmaceuticals | Precigen PGENNASDAQ · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $330B | $1.51B |
| Revenue, last fiscal year | $65B | $9.68M |
| Net income, last fiscal year | $18.3B | −$251M |
| Net marginNet income as a share of revenue | 28.1% | -2588.2% |
| Free cash flow | $12.4B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Merck against
Common questions
How is Merck different from Precigen?
Merck (MRK) is in Pharmaceuticals on NYSE, with $65B of revenue in its last fiscal year and a net margin of 28.1%. Precigen (PGEN) is in Pharmaceutical Preparations on NASDAQ, with $9.68M of revenue in its last fiscal year and a net margin of -2588.2%. The biggest part of Merck's revenue is Pharmaceutical, 89% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Merck and Precigen compare in size?
Merck has the larger market value: Merck $330B and Precigen $1.51B, at the last close.
Whose share price rose more over the last 12 months, MRK or PGEN?
Over the last 12 months Merck moved +40.8% and Precigen +8.0%. Past price moves say nothing about the future.
Which has had more insider buying, Merck or Precigen?
Since 2006, Precigen insiders reported 287 open-market purchases against 30 for Merck. These are counts of what was filed, not a view on either stock.
Do members of Congress trade MRK or PGEN?
In the last 12 months, members of Congress disclosed 9 trades in Merck (MRK) and 0 in Precigen (PGEN).
When did insiders last buy MRK and PGEN?
Merck: Feb 7, 2025. Precigen: Sep 30, 2025.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Merck pagePrecigen pageRare insider trades this weekAll comparisons
https://oqro.io/compare/mrk-vs-pgen







